Table 4.
Stepwise genotyping of msp2 and msp1 in paired samples collected from children with uncomplicated P. falciparum malaria participating in an anti-malarial drug trial in Zanzibar.
| msp2 | msp1 | ||||||
| Outcome | Child (study ID) | Daya | FC27b | ICb | K1b | MAD20b | RO33b |
| Recrudescences | K152 | 0 | - |
599.84 505.26 |
- | - | 157.51 |
| K152 | 21 | - | 599.76 | - | - | 157.50 | |
| K97 | 0 | - | 559.63 | 246.15 | - | - | |
| K97 | 21 | - | 559.62 | 246.05 | - | - | |
| M107 | 0 | - | 523.93 | - | 220.00 | - | |
| M107 | 21 | - | 523.93 | - | 220.00 | - | |
| M131 | 0 | - | 487.40 | - | 202.01 | - | |
| M131 | 21 | - | 487.33 | - | 202.01 | - | |
| M152 | 0 | - | 528.70 | 219.25 | - | - | |
| M152 | 21 | - | 528.61 | 219.26 | - | - | |
| New infections | K108 | 0 | 336.25 | 515.38 | - | - | 157.53 |
| K108 | 42 | 336.25 | - | 246.43 | - | - | |
| K149 | 0 | 336.30 | 452.49 | 182.77 | 201.89 | - | |
| K149 | 28 | 336.24 | 580.85 | 300.79 | 210.91 | - | |
| M161 | 0 | 336.30 | 531.02 | 138.73 146.36 |
210.81 220.07 |
- | |
| M161 | 21 |
335.75 419.85 |
622.87 | 182.72 210.17 |
192.88 | 157.62 | |
| M164 | 0 |
336.30 419.71 |
632.64 620.97 |
228.45 | - | - | |
| M164 | 28 | 336.30 | 560.93 | 255.70 264.91 |
- | 157.53 | |
| M165 | 0 | 335.91 373.27 |
464.33 | 210.07 | 210.81 | 157.61 | |
| M165 | 28 |
372.97 419.71 |
- | 228.28 | - | - | |
| M173 | 0 | 372.85 | 531.85 | 246.31 | 220.0 228.15 |
- | |
| M173 | 42 | 372.14 | 499.35 564.54 |
201.10 264.10 |
246.88 | - | |
Outcome classified by msp2 followed by msp1 genotyping to confirm recrudescence (bold) or new infection.
a Paired blood samples collected before initiation of anti-malarial treatment (day 0) and at day of recurrent parasitaemia (days 21–42)
b Fragment sizes in bp
- negative result